SEC Comment Letter for GUIDED THERAPEUTICS INC (GTHP) (CIK 0000924515) (GTHP) — Sep 14, 2020

GUIDED THERAPEUTICS INC (GTHP) (CIK 0000924515)
Date: Sept. 14, 2020 · CIK: 0000924515 · Accession: 0000000000-20-008646

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-248712

Date

September 14, 2020

Author

Not clearly detected

Form

UPLOAD

Company

GUIDED THERAPEUTICS INC (GTHP) (CIK 0000924515)

Letter

United States securities and exchange commission logo September 14, 2020 Gene S. Cartwright, Ph.D. President and Chief Executive Officer Guided Therapeutics, Inc. 324 S. Hyde Park Avenue, Ste. 350 Tampa, Florida 33606 Re:Guided Therapeutics, Inc. Registration Statement on Form S-1 Filed September 10, 2020 File No. 333-248712 Dear Dr. Cartwright: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Robert F. Charron, Esq.

Show Raw Text

United States securities and exchange commission logo
September 14, 2020
Gene S. Cartwright, Ph.D.
President and Chief Executive Officer
Guided Therapeutics, Inc.
324 S. Hyde Park Avenue, Ste. 350
Tampa, Florida 33606
Re:Guided Therapeutics, Inc.
Registration Statement on Form S-1
Filed September 10, 2020
File No. 333-248712
Dear Dr. Cartwright:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Robert F. Charron, Esq.

SecProbe.io